近年來血管內(nèi)皮生長因子（VEGF）及其受體（VEGFR）成為抗腫瘤藥物研發(fā)的重要靶點。甲磺酸阿帕替尼是一種抗VEGFR-2的小分子靶向藥，用于晚期胃癌治療。臨床研究發(fā)現(xiàn)阿帕替尼不僅對胃癌療效顯著，而且在非小細胞肺癌、結(jié)直腸癌、乳腺癌等多種癌癥的治療中也有顯著療效。其臨床用藥形式從單獨用藥逐步發(fā)展為與多種治療模式的聯(lián)合應(yīng)用。根據(jù)阿帕替尼的臨床用藥形式，分別從單獨用藥、聯(lián)合其他化療藥用藥、聯(lián)合放療用藥等方面闡釋阿帕替尼抗腫瘤的有效性和安全性，為臨床合理用藥提供參考。

In recent years, vascular endothelial growth factor (VEGF) and its receptor (VEGFR) have become important targets in the research and development of antineoplastic drugs. Apatinib mesylate is a small molecule targeting drug against VEGFR-2, which is used in the treatment of advanced gastric cancer. Clinical studies have found that apatinib is not only effective in the treatment of gastric cancer, but also in the treatment of non-small cell lung cancer, colorectal cancer, breast cancer and other cancers. The clinical application of apatinib has gradually developed from single drug use to combined application with a variety of treatment modes. According to the clinical application form of apatinib, the efficacy and safety of apatinib in anti-tumor were interpreted from the aspects of apatinib alone, combination with other chemotherapy drugs and combination with radiotherapy etc., so as to provide reference for clinical rational use of drugs.

R979.1